Sprunglinks

News

You are here: / / Immuno-Oncology Discovery from Bristol-Myers Squibb published in Natur...

Immuno-Oncology Discovery from Bristol-Myers Squibb published in Nature

Immuno-Oncology Discovery from Bristol-Myers Squibb published in Nature

„Vista is an acidic pH selective ligand for PSGL-1“ Identification of a new immune-oncology drug target using the LRC-TriCEPS platform on primary human T-cells.
2019-10-30T06:05:00+00:00
The University of Oklahoma – Health Sciences CenterSeoul National University
DO YOU WANT TO TEST IT NOW?
Transport not incl. Your Information will never be shared with any third party.
To get pretest TriCEPS Material please contact us!

Identify the targets of your ligand on the living cells. Prior to the main experiment get free TriCEPS Material to test the functionality of your TriCEPS coupled ligand.
  • Extracellular proteins
  • Peptide ligands
  • Antibodies
  • Engineered affinity binders
  • Viruses
DO YOU WANT TO TALK TO US?
Your information will never be shared with any third party.
LRC-TriCEPS to identify targets on the surface of living cells.

Please provide your email address and we will contact you to arrange a call.
  • Small molecules
  • Extracellular proteins
  • Peptide ligands
  • Antibodies
  • Engineered affinity binders
  • Viruses